Experimental J&J drug works in resistant TB -study
BOSTON, June 3 (Reuters) - Johnson & Johnson's (JNJ.N: Quote, Profile, Research) experimental drug designed to starve the bacteria responsible for tuberculosis is five times more effective than older drugs at treating people with drug-resistant TB, doctors reported on Wednesday.
The company-run study found that the drug TMC207, if added to a standard cocktail of five other TB medicines, cleared traces of the tuberculosis bacteria in the sputum of 48 percent of the volunteers after eight weeks. Only 9 percent of placebo recipients showed that type of improvement.
© Thomson Reuters 2009 All rights reserved
Pledge to support economies
G20 financial leaders pledged to prepare strategies to end emergency support for their economies, but to keep the aid flowing until recovery was assured. Full Article | Related Story
Galleon case
U.S. insider trading probe widens
Fourteen people were charged with fraud and conspiracy in a dramatic widening of an insider trading scandal. Full Article
India
US
UK
